CD200 is a type-1a transmembrane cell-surface glycoprotein that is normally expressed in critical tissues such as the central nervous system and testis, as well as certain leukocytes, including T and B lymphocytes, where its role is to promote peripheral tolerance and protect immune privileged sites.1 CD200 has no known intracellular signaling motif, but induces immunosuppression through engagement with CD200R, a cell-surface receptor homolog, which is expressed on leukocytes of myeloid lineage, including mast-cells, macrophages, basophils, dendritic cells as well as certain T-cell populations.2 CD200, which is frequently overexpressed in acute myeloid leukemia (AML) patient blasts and associated with a worse outcome,3 has the potential to induce the formation of CD4+CD25++FoxP3+ regulatory T cells (Tregs),4 a subset of immunosuppressive T cells that are linked with a poor prognosis in AML.5 Most importantly, Tregs have been documented to suppress the anti-leukemia response in vitro from AML patients,6 suggesting that these cells have an important role in regulating AML patient tumor immunity. We therefore investigated whether CD200 protein expression on human AML blasts was associated with an increased frequency of Treg cells in AML using a cohort of 40 AML patients (at the point of diagnosis before to any treatment; Supplementary Table S1 for patient demographic). AML blast CD200 protein expression and patient Treg frequency was analyzed by flow cytometry (for full gating strategy, refer to Supplementary Figure S1). The data show that CD200 blast expression level correlated significantly with the frequency of Treg cells (Figure 1a). This association was found to be independent of white blood cell count (Figure 1b), suggesting that CD200 expression on AML blasts promotes Treg formation. We also examined whether CD200 expression was differentially expressed on AML blasts with a putative leukemic stem cell phenotype (CD34+CD38−),7 but could find no evidence for this within the six samples examined (Supplementary Figure S2).
Given that the depletion of Tregs has been shown to improve T-cell-mediated therapy, as well as improving antitumor activity in leukemia patients that are in complete remission;8, 9 we investigated whether Tregs from CD200hi patients were functionally immunosuppressive. We examined the ability of purified Tregs to suppress naïve responder T-cell (CD4+CD25−) proliferation following CD3/CD28 co-stimulation (refer to Supplementary Materials and Methods). The data demonstrate that Tregs isolated from CD200hi AML patients were capable of suppressing T-cell proliferation at responder to Treg ratios of >1 to 0.01 (Figure 1c). Reciprocal analysis of Tregs from CD200lo patients could not be carried out because of the extremely low frequencies of these cells in CD200lo patients (Figure 1d). In fact, Treg frequencies in CD200lo AML patients were uniformly lower than in healthy donor controls, suggesting that CD200 has an influence on Treg induction in this context.
Since mouse models have suggested that CD200-induced Tregs are likely to mediate Th1 immunosuppression,10 a cytokine response with a prognostic link in leukemia,11 we measured the Th1 cytokine response (TNFα, IL2 and IFNγ production) in CD200hi patients before and after Treg depletion. Representative flow cytometric plots confirmed Treg depletion using magnetic separation (Figure 2a). However, removal of Tregs alone was insufficient to significantly improve the Th1 cytokine response as detected by intracellular cytokine staining (Figure 2b). Elsewhere we report that, in addition to its known influence on Treg production, CD200 is also directly immunosuppressive through engagement with CD200R on T cells in AML.12 However, in the present study we show that removal of Treg cells alone is unlikely to show effect in these assays when large numbers of CD200+ blast cells are present. These data would predict that Tregs have little impact on immunosuppression at diagnosis when the disease burden is high, as the dominant mode of T-cell suppression would be mediated by CD200hi blasts directly inhibiting Th1 responses.12 Conversely, following chemotherapy, the reduction of tumor burden would be predicted to make Treg-mediated immunosuppression cells the dominant factor.
In summary, these findings illustrate a clear correlation between blast CD200 expression level and the frequency of immunosuppressive Treg cells. Previous studies of human AML have also reported increased frequencies of Tregs in untreated disease13 as well as during regeneration following treatment,14 however, the link with CD200 expression has not previously been established. Our data also indicate that while Tregs in these patients may be functionally immunosuppressive, they may only become influential following cytoreduction. Indeed, several studies have identified that increased frequencies of Tregs are associated with relapse in myeloid malignancy.15, 16 Furthermore, phase-I studies using anti-CD200 monoclonal antibody immunotherapy have shown that blocking CD200 is sufficient to reduce the Treg frequency in chronic lymphocytic leukemia patients,17 illustrating that blocking CD200 may be therapeutically advantageous in AML.
References
Wright GJ, Jones M, Puklavec MJ, Brown MH, Barclay AN . The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans. Immunology 2001; 102: 173–179.
Wright GJ, Cherwinski H, Foster-Cuevas M, Brooke G, Puklavec MJ, Bigler M et al. Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol 2003; 171: 3034–3046.
Tonks A, Hills R, White P, Rosie B, Mills KI, Burnett AK et al. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 2007; 21: 566–568.
Gorczynski RM, Lee L, Boudakov I . Augmented induction of CD4+CD25+ Treg using monoclonal antibodies to CD200R. Transplantation 2005; 79: 488–491.
Shenghui Z, Yixiang H, Jianbo W, Kang Y, Laixi B, Yan Z et al. Elevated frequencies of CD4(+)CD25(+)CD127(lo) regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int J Cancer 2010; 129: 1373–1381.
Curti A, Trabanelli S, Onofri C, Aluigi M, Salvestrini V, Ocadlikova D et al. Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. Haematologica 2010; 95: 2022–2030.
Bonnet D, Dick JE . Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730–737.
Zhou Q, Bucher C, Munger ME, Highfill SL, Tolar J, Munn DH et al. Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. Blood 2009; 114: 3793–3802.
Maury S, Lemoine FM, Hicheri Y, Rosenzwajg M, Badoual C, Cherai M et al. CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation. Sci Transl Med 2010; 2: 41ra52.
Gorczynski L, Chen Z, Hu J, Kai Y, Lei J, Ramakrishna V et al. Evidence that an OX-2-positive cell can inhibit the stimulation of type 1 cytokine production by bone marrow-derived B7-1 (and B7-2)-positive dendritic cells. J Immunol 1999; 162: 774–781.
Gallego A, Vargas JA, Castejon R, Citores MJ, Romero Y, Millan I et al. Production of intracellular IL-2, TNF-alpha, and IFN-gamma by T cells in B-CLL. Cytometry B Clin Cytom 2003; 56: 23–29.
Coles SJ, Hills RK, Wang ECY, Burnett AK, Man S, Darley RL et al. Expression of CD200 on AML blasts directly suppresses memory T-cell function. Leukemia 2012; 26: 2148–2151.
Szczepanski MJ, Szajnik M, Czystowska M, Mandapathil M, Strauss L, Welsh A et al. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res 2009; 15: 3325–3332.
Ersvaer E, Liseth K, Skavland J, Gjertsen BT, Bruserud O . Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells. BMC Immunol 2010; 11: 38.
Delluc S, Hachem P, Rusakiewicz S, Gaston A, Marchiol-Fournigault C, Tourneur L et al. Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response. Cancer Immunol Immunother 2009; 58: 1669–1677.
Nadal E, Garin M, Kaeda J, Apperley J, Lechler R, Dazzi F . Increased frequencies of CD4(+)CD25(high) T(regs) correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2007; 21: 472–479.
Mahadevan D, Lanasa MC, Whelden M, Faas SJ, Ulery TL, Kukreja A et al. First-In-Human Phase I Dose Escalation Study of a Humanized Anti-CD200 Antibody (Samalizumab) In Patients with Advanced Stage B Cell Chronic Lymphocytic Leukemia (B-CLL) or Multiple Myeloma (MM). 52nd ASH Annu Meet Exposition. 2465; Orlando, FL; 2012.
Acknowledgements
This work was funded by Leukemia and Lymphoma Research UK. We thank Gareth Betts (Cardiff University) for his technical assistance in analyzing Tregs. We are grateful to the patients for access to material enrolled in the NCRI clinical trials. Dr Steve Coles is currently funded by NISCHR, Wales, UK.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Author Contributions
SJC designed and performed the experiments/analyzed all data and co-wrote the manuscript. RKH provided statistical guidance. ECYW provided biological insight. AKB provided resources and clinical insight. SM, RLD and AT contributed to experimental design and co-wrote the manuscript.
Supplementary Information accompanies the paper on the Leukemia website
Rights and permissions
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Coles, S., Hills, R., Wang, E. et al. Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells. Leukemia 26, 2146–2148 (2012). https://doi.org/10.1038/leu.2012.75
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2012.75
This article is cited by
-
The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways
Cell Communication and Signaling (2023)
-
Regulatory T cells promote the stemness of leukemia stem cells through IL10 cytokine-related signaling pathway
Leukemia (2022)
-
Alterations of T-cell-mediated immunity in acute myeloid leukemia
Oncogene (2020)
-
Cellular distribution of CD200 receptor in rats and its interaction with cytomegalovirus e127 protein
Medical Microbiology and Immunology (2018)
-
The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse
Leukemia (2015)